following a full submission assessed under the end of life process.
pemetrexed (Alimta®) is accepted for use within NHS Scotland.
Indication under review: monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
In patients with locally advanced or metastatic non-squamous non-small cell lung cancer, maintenance treatment with pemetrexed, following completion of first-line platinum-based chemotherapy, was associated with prolonged overall survival and progression-free survival when compared with placebo.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice187KB (PDF)
Medicine details
- Medicine name:
- pemetrexed (Alimta)
- SMC ID:
- 770/12
- Indication:
- monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2014
This supersedes previous advice for pemetrexed (Alimta) (SMC No. 642/10).